Vaxcyte Confident Of Pneumococcal Vaccine Dominance After Phase I/II Results

Phase III Adult Trials To Begin In 2025

 
• By Mandy Jackson

The company’s VAX-31 against 31 pneumococcal serotypes outperformed Pfizer’s market-leading Prevnar 20 and could provide the broadest coverage of any vaccine in its class.

Pneumococcal vaccine in a vial, immunization and treatment of infection, vaccine used for disease prevention
Vaxcyte will initiate adult and infant trials for VAX-31 in 2025 • Source: Shutterstock

More from Clinical Trials

More from R&D